Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 3 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer.
Cancers (Basel). 2023 Mar 28;15(7):2015. doi: 10.3390/cancers15072015.
Cancers (Basel). 2023.
PMID: 37046675
Free PMC article.
Review.
Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer.
Molto Valiente C, Amir E.
Molto Valiente C, et al.
Transl Cancer Res. 2023 Jul 31;12(7):1887-1890. doi: 10.21037/tcr-23-365. Epub 2023 Jul 3.
Transl Cancer Res. 2023.
PMID: 37588734
Free PMC article.
No abstract available.
Item in Clipboard
Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
Adam R, Tibau A, Molto Valiente C, Šeruga B, Ocaña A, Amir E, Templeton AJ.
Adam R, et al. Among authors: molto valiente c.
PLoS One. 2022 Jun 10;17(6):e0268545. doi: 10.1371/journal.pone.0268545. eCollection 2022.
PLoS One. 2022.
PMID: 35687539
Free PMC article.
Item in Clipboard
Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis.
Mittal A, Molto Valiente C, Tamimi F, Di Iorio M, Al-Showbaki L, Cescon DW, Amir E.
Mittal A, et al. Among authors: molto valiente c.
JNCI Cancer Spectr. 2023 Jul 3;7(4):pkad040. doi: 10.1093/jncics/pkad040.
JNCI Cancer Spectr. 2023.
PMID: 37243731
Free PMC article.
Item in Clipboard
Magnitude of effect and sample size justification in trials supporting anti-cancer drug approval by the US Food and Drug Administration.
Nadler MB, Wilson BE, Desnoyers A, Valiente CM, Saleh RR, Amir E.
Nadler MB, et al. Among authors: valiente cm.
Sci Rep. 2024 Jan 3;14(1):459. doi: 10.1038/s41598-023-50694-0.
Sci Rep. 2024.
PMID: 38172190
Free PMC article.
Item in Clipboard
Cite
Cite